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starting and maintenance doses were ≤0.5 DDD/day for 
tricyclic antidepressants and 0.5–1 DDD/day for SSRIs and 
other antidepressants. Starting doses were guideline-con-
cordant 58 % of the time for children, 31 % for preteens, 
and 16 % for teens. Sixty percent of teens were prescribed 
an adult starting dose. In conclusion, guideline adherence 
was poor. Physicians preferred citalopram over fluoxetine, 
in contrast to the recommendations. Furthermore, although 
children were prescribed a low starting dose relatively fre-
quently, teens were often prescribed an adult starting dose. 
These results suggest that dedicated effort may be necessary 
to improve guideline adherence.
Keywords Antidepressants · Guidelines · Children and 
adolescents · Dosing · Prescription trends
Introduction
Practice guidelines in the Netherlands [1] and interna-
tionally [e.g., 2] recommend that medication should only 
be prescribed to children and adolescents suffering from 
(moderate to) severe depression. These guidelines also 
recommend that pharmacotherapy should be initiated with 
fluoxetine, with sertraline or citalopram used in case of 
non-response to fluoxetine. Other antidepressants, such as 
mirtazapine, venlafaxine, and tricyclic antidepressants, are 
not recommended. In addition, treatment should be initi-
ated with a low starting dose (a quarter to a half of the adult 
starting dose) [3, 4].
Second-generation antidepressants may be moderately 
effective for depression in children and adolescents [5], 
but they have also been associated with an increased risk 
of suicidal ideation and behavior [6]. In 2004, the United 
States Food and Drug Administration issued a black box 
Abstract The Dutch guideline for the treatment of depres-
sion in young people recommends initiating antidepressant 
treatment with fluoxetine, as the evidence for its efficacy is 
strongest and the risk of suicidality may be lower than with 
other antidepressants. Furthermore, low starting doses are 
recommended. We aimed to determine whether antidepres-
sant prescriptions are in accord with guidelines. A cohort of 
young people aged between 6 and 17 at the time of antide-
pressant initiation was selected from IABD, a Dutch phar-
macy prescription database. The percentage of prescriptions 
for each antidepressant was determined. Starting and main-
tenance doses were determined and compared with recom-
mendations for citalopram, fluoxetine, fluvoxamine, and 
sertraline. During the study period, 2942 patients initiated 
antidepressant treatment. The proportion of these young 
people who were prescribed fluoxetine increased from 
10.1 % in 1994–2003 to 19.7 % in 2010–2014. However, the 
most commonly prescribed antidepressants were paroxetine 
in 1994–2003 and citalopram in 2004–2014. The median 
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warning on antidepressants to emphasize the risk of suici-
dality in young people. There is some evidence to suggest 
that the risk may vary by antidepressant, with fluoxetine 
showing less of an increased risk than many other second-
generation antidepressants [7]. The risk of suicidality may 
also be dose-related, with young people prescribed higher-
than-modal starting doses of antidepressants showing an 
increased risk of suicidal behavior compared to those pre-
scribed the modal dose [8]. Further epidemiological evi-
dence in adults also suggests that lower-than-modal doses 
may be associated with decreased risk, although confound-
ing by indication cannot be excluded. This study also found 
that risk was particularly increased within the first 3 months 
after starting an antidepressant [9].
Although prescription trends in children have been 
examined extensively [e.g., 10–17], most studies have not 
examined specifically the first prescription of an antide-
pressant and only one study, to our knowledge, has exam-
ined whether appropriate dosages are used [18]. This study 
found that antidepressant treatment in young people in the 
USA was more commonly initiated with a low dose after 
the black box warning was issued in 2004, although low 
doses were still only prescribed in a minority of cases. In 
the Netherlands, health insurance reimbursements show 
that citalopram is the most commonly prescribed anti-
depressant to young people [19], which suggests that the 
guidelines may not be followed; however, as this includes 
all antidepressant prescriptions and citalopram is recom-
mended as a second antidepressant, the evidence is not yet 
conclusive. To our knowledge, no evidence is currently 
available regarding antidepressant dosing in the Nether-
lands. In the current study, we therefore aimed to answer 
the following questions: first, do physicians initiate antide-
pressant treatment in young people with fluoxetine? Sec-
ond, what are the usual starting and maintenance doses of 




Prescription data were obtained from the IADB database, 
which contains information on prescriptions filled in com-
munity pharmacies in the Netherlands between 1994 and 
2014 [20]. The population included in the database in any 
given year is currently approximately 600,000. Patients are 
included in the database the first time they fill a prescrip-
tion in one of the participating pharmacies. The database 
includes information about the patient (gender, date of 
birth) and the prescription [fill date, Anatomical Therapeu-
tical Chemical (ATC) code, number of tablets, daily dose 
(in number of tablets), and the total number of defined daily 
doses (DDDs) in the prescription]. A DDD is defined as the 
assumed average maintenance dose for a drug used for its 
main indication in adults [21]. All outpatient prescriptions 
are included in the database, but inpatient prescriptions and 
over-the-counter medications are not.
Patient selection
From the IADB database, a cohort of young patients ini-
tiating treatment with an antidepressant was selected. We 
included tricyclic antidepressants (ATC-code N06AA), 
selective serotonin reuptake inhibitors (SSRIs, ATC-code 
N06AB), and other antidepressants (N06AX). Monoam-
ine oxidase inhibitors (selective and non-selective MAOIs, 
ATC-codes N06AF and N06AG) were not included, as it 
is unlikely that a MAOI would be prescribed as the first 
antidepressant. Patients were included in the cohort if they 
were between 6 and 17 years of age (inclusive), had been 
included in the database for at least 6 months at the time 
of first prescription of an antidepressant, and had not pre-
viously received a prescription for a different antidepres-
sant. Patients aged between six and nine were categorized 
as children; patients aged between ten and thirteen as pre-
teens; and patients aged between fourteen and seventeen 
as teens. For patients who had multiple episodes of antide-
pressant treatment during the study period, we only consid-
ered data from the first eligible treatment episode.
We excluded patients who were likely prescribed an 
antidepressant for non-psychiatric indications, specifi-
cally bed-wetting and pain. Patients starting on amitrip-
tyline or imipramine who also received a prescription for 
desmopressin (H01BA02), the first-line treatment for bed-
wetting, at any time during the study period were excluded 
(238 patients). We also excluded patients who received two 
or more prescriptions for pain-related medication within 
6 months prior to initiation of a tricyclic antidepressant 
(111 patients). Pain-related medication was defined as any 
medication with ATC-code M01 (anti-inflammatory and 
anti-rheumatic drugs), N02 (analgesics), N03AX12 (gabap-
entin), and N03AX16 (pregabalin). One patient received a 
first prescription for two different antidepressants on the 
same day and was also excluded.
Data analysis: type of antidepressant
We split the data into three time periods: 1994 through 
2003, 2004 through 2009, and 2010 through 2014. These 
time periods were chosen based upon major events: in 
2004, knowledge of a possible link between antidepres-
sants and suicidality in children became widespread, while 
in December 2009, the youth addendum to the Dutch Mul-
tidisciplinary Guideline for Depression was published.
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We determined which antidepressant was first prescribed 
to each patient and calculated the percentage of patients 
who were prescribed fluoxetine as their first antidepressant. 
Possible moderators were examined by stratifying the data 
based upon prescriber (general practitioner (GP) or special-
ist) and age group (child, preteen, or teen).
Data analysis: starting and maintenance dose
We determined the starting dose of antidepressants (in 
DDD/day) for each patient. A conversion of DDDs to the 
equivalent dose in milligrams for the ten most commonly 
prescribed antidepressants is provided in Table 1. The dose 
was calculated as the total number of DDDs divided by the 
total number of days in the first prescription. The number 
of days was calculated by dividing the total number of units 
(pills) by the number of pills to take daily. For patients who 
received multiple prescriptions for the same antidepres-
sant on the same day, we took the prescription with the 
lowest daily dose. Additionally, for prescriptions for the 
highly concentrated liquid formulations of citalopram and 
escitalopram, we divided the daily dose by 20 (as 1 drop 
of solution is approximately equivalent to 0.05 ml) before 
calculating the DDD/day. We excluded patients with miss-
ing daily doses [4 (0.1 %) patients] or with unrealistically 
low [0 DDD/day, 256 (8.7 %) patients] or high [>3 DDD/
day, 6 (0.2 %) patients] doses, as these are likely to reflect 
data entry errors (in particular, entering 0 as the number of 
units per day).
The maintenance dose of antidepressants was deter-
mined in a similar fashion. Maintenance was defined as a 
period in which at least two prescriptions with the same 
dose were filled, containing a minimum of 60 days’ sup-
ply. Prescriptions were required to be overlapping, i.e., 
the number of days in the first prescription must be suf-
ficient to cover the fill date of the subsequent prescrip-
tion, after adding 25 % to the number of days to account 
for possible non-compliance. For patients who had multi-
ple maintenance periods, we selected the period with the 
longest duration and the highest dose (if multiple periods 
had the same duration). Missing doses were set to 0. We 
excluded patients with unrealistically low [0 DDD/day, 8 
(0.1 %) patients] or high maintenance doses (>4 DDD/day, 
0 patients). Fifty-three percent of all patients had at least 
one maintenance period with a realistic dose.
The distribution of starting doses and maintenance doses 
was determined for each antidepressant. For the SSRIs 
fluoxetine, citalopram, sertraline, and fluvoxamine, the 
distribution was compared to the Dutch dosing guidelines 
for children [3, 4]. These guidelines recommend a starting 
dose of 5 mg (0.25 DDD) for fluoxetine and citalopram, 
and 25 mg (0.25 DDD) for fluvoxamine. For sertraline, the 
guidelines both recommend 25 mg (0.5 DDD) for young 
children, but one guideline recommends a higher dose of 
50 mg (1 DDD) for adolescents aged 13 and older [3]. We 
chose to compare the distribution to the latter, more leni-
ent guideline. Subsequently the data were stratified by pre-
scriber and by age group to examine the possible moder-
ating influence of these variables. We also examined how 
many patients were prescribed a starting dose of fluoxetine 
of 10 mg or less, as recommended in international guide-
lines (e.g., United Kingdom [2]).
Results
Demographics
A total of 2942 patients were prescribed a first antidepres-
sant during the study period and met inclusion criteria: 
1194 in 1994–2003, 815 in 2004–2009, and 933 in 2010–
2014. Of these patients, 1739 (59 %) were female, 1188 
(40 %) were male, and for 15 (1 %) information about sex 
was missing. The average age of the sample at initiation 
was 14.2 years. Three-hundred and eleven (11 %) patients 
were children, 573 (19 %) were preteens, and 2058 (70 %) 
were teens. The majority of patients (62 %) received their 
first prescription for an antidepressant from their GP in 
1994–2003, but by 2010–2014 69 % of patients received 
their first prescription from a specialist.
First antidepressant
Of all young people initiating treatment with an antidepres-
sant, the proportion prescribed fluoxetine increased dur-
ing the study period from 10.1 % in 1994–2003 to 19.7 % 
in 2010–2014 (Fig. 1), but fluoxetine was never the most 
commonly prescribed antidepressant. Instead, antidepres-
sant treatment was most commonly initiated with parox-
etine in 1994–2003 and with citalopram from 2004 onward. 
Table 1  Dose in milligrams equivalent to 1 defined daily dose 
(DDD) of the ten most commonly prescribed antidepressants
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A full listing of all antidepressants is provided in supple-
mental Table 1.
Stratification by prescriber (Fig. 2) showed that special-
ists were slightly more likely to prescribe fluoxetine than 
GPs at each time point. In 2010–2014, GPs initiated treat-
ment with fluoxetine in 15.8 % of cases, while specialists 
did so in 21.5 % of all cases. Specialists most commonly 
initiated treatment with citalopram, while GPs most com-
monly initiated treatment with amitriptyline. Both GPs and 
specialists showed a steep decrease in the use of paroxe-
tine, although this decrease occurred earlier for specialists 
than for GPs.
Stratification by age group showed low rates of anti-
depressant initiation with fluoxetine in each age group 
(Fig. 3). Children were prescribed fluoxetine least fre-
quently (<6.5 % throughout the study period). Preteens 
were prescribed fluoxetine in 8.6 % of cases in 1994–2003, 
increasing to 15.2 % in 2010–2014. Teens were prescribed 
fluoxetine relatively frequently, at 11.4 % in 1994–2003 
and 22.9 % in 2010–2014. Citalopram was the most com-
monly prescribed antidepressant in all age groups by 
2010–2014. In particular, children and preteens received 
citalopram in 70.9 and 56.0 % of cases, respectively, in 
2010–2014.
Fig. 1  Percentage of young people prescribed one of the ten most 
commonly prescribed antidepressants in each time period. Prescrip-
tions for all other antidepressants are combined into the category 
“others”
Fig. 2  Percentage of young 
people prescribed one of the 
ten most commonly prescribed 
antidepressants in each time 
period, stratified by prescriber. 
Prescriptions for all other anti-
depressants are combined into 
the category “others”
1165Eur Child Adolesc Psychiatry (2016) 25:1161–1170 
1 3
Starting doses
The distribution of starting doses for the 10 most com-
monly prescribed antidepressants is shown in Fig. 4. A 
full listing is given in supplemental Table 2. The median 
starting dose for tricyclic antidepressants was quite low, 
at around 0.1–0.3 DDD/day. For SSRIs, the median start-
ing dose was 1 DDD/day for fluoxetine, paroxetine, and 
Fig. 3  Percentage of young people prescribed one of the ten most commonly prescribed antidepressants in each time period, stratified by age 
group. Prescriptions for all other antidepressants are combined into the category “others”
Fig. 4  Distribution of starting 
doses for the ten most com-
monly prescribed antidepres-
sants. The starting dose is 
expressed as the number of 
DDDs per day, where 1 DDD is 
defined as the assumed average 
maintenance dose for a drug 
used in its main indication in 
adults. The numbers below the 
boxplots indicate the number of 
prescriptions for that antide-
pressant
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sertraline, while it was 0.5 DDD/day for citalopram and 
fluvoxamine. Mirtazapine and venlafaxine had median 
starting doses of 0.5 and 0.75 DDD/day, respectively. A 
minority of first prescriptions (22.2 %) were according to 
guidelines: 6.5 % for fluoxetine, 24.9 % for citalopram, 
86.5 % for sertraline, and 14.5 % for fluvoxamine.
Median starting doses were similar throughout the 
study period for most antidepressants, but decreased for 
citalopram, paroxetine, mirtazapine, and venlafaxine. For 
citalopram, the median starting dose decreased from 1 
DDD/day in 1994–2003 to 0.4 DDD/day in 2010–2014; 
for paroxetine and mirtazapine, the median starting dose 
decreased from 1 DDD/day in 1994–2003 to 0.5 DDD/
day in 2010–2014; and for venlafaxine, the median start-
ing dose decreased from 0.75 DDD/day in 1994–2003 to 
0.375 DDD/day in 2010–2014. Guideline adherence also 
improved somewhat within the study period for citalopram 
and fluvoxamine, with adherence rates being 44.3 % for 
citalopram and 28.6 % for fluvoxamine in 2010–2014.
Stratification by prescriber showed few differences 
between prescribers, although specialists prescribed some 
SSRIs in slightly lower doses than GPs. Stratification by 
age showed that children tended to be prescribed lower 
doses (≤0.5 DDD/day), particularly for the SSRIs. Pre-
teens received slightly higher doses: 0.5 DDD/day for all 
SSRIs except sertraline (1 DDD/day). Teens received the 
highest doses, at 1 DDD/day for all SSRIs except fluvox-
amine (0.5 DDD/day). Table 2 shows the percentage of first 
prescriptions according to guidelines for fluoxetine, citalo-
pram, sertraline, and fluvoxamine, stratified by age group. 
Children were reasonably likely to be prescribed accord-
ing to guidelines (58 % across all four antidepressants), 
although 10 % of children were prescribed an adult start-
ing dose. On the other hand, very few teens (16 %) were 
prescribed according to guidelines, while 60 % of teens 
were prescribed an adult starting dose. For fluoxetine spe-
cifically, 33 % of children, 16 % of preteens and 3 % of 
teens received a guideline-compliant dose (≤0.25 DDD/
day). The corresponding percentages for a fluoxetine dose 
of ≤0.5 DDD/day (10 mg) were 67 % for children, 58 % 
for preteens, and 30 % for teens.
Maintenance doses
Maintenance doses were similar to starting doses (sup-
plemental Table 3). The median maintenance dose for tri-
cyclic antidepressants was around 0.2–0.3 DDD/day. For 
SSRIs, the median maintenance dose was 1 DDD/day. For 
the other antidepressants, median maintenance doses were 
0.5 DDD/day for mirtazapine and 0.75 DDD/day for venla-
faxine. Maintenance doses were nearly always according to 
guidelines for fluoxetine (98 %), citalopram (96 %), sertra-
line (91 %), and fluvoxamine (93 %).
Among those who had a valid starting dose as well as 
a valid maintenance dose, 60 % remained at their start-
ing dose, while 35 % titrated up to a higher dose and 5 % 
titrated down. These percentages were similar across pre-
scribers and age groups; however, they did vary according 
to the antidepressant prescribed. Of the 10 most commonly 
prescribed antidepressants, up-titration was more likely 
for citalopram (46 %), sertraline (42 %), and venlafaxine 
(47 %), while it was less likely for imipramine (25 %), 




Physicians initiated pharmacotherapy with fluoxetine less 
than 20 % of the time, even after publication of the guide-
lines for youth in 2009. The percentage of first prescrip-
tions for paroxetine decreased sharply after 2003, a trend 
which is most likely due to its particularly prominent 
association with suicidality in young people. Our results 
Table 2  Comparison of antidepressant starting dose with guidelines and with adult doses
n indicates the number of prescriptions that were at or below the guideline dose, while N indicates the total number of prescriptions for all four 
antidepressants in that age group
Guideline-compliant dose Adult dose (≥1 DDD/day)
Child (N = 115) Preteen (N = 295) Teen (N = 961) Child (N = 115) Preteen (N = 295) Teen (N = 961)
n (%) n (%) n (%) n (%) n (%) n (%)
Fluoxetine 5 (33.3) 10 (16.1) 11 (3.4) 2 (13.3) 25 (40.3) 222 (69.2)
Citalopram 49 (66.2) 62 (36.3) 60 (13.6) 6 (8.1) 32 (18.7) 231 (52.4)
Sertraline 3 (60.0) 13 (72.2) 67 (91.8) 2 (40.0) 10 (55.6) 62 (84.9)
Fluvoxamine 4 (36.4) 6 (13.0) 14 (13.0) 0 (0.0) 8 (17.4) 50 (46.3)
Total 61 (58.1) 91 (30.8) 152 (15.8) 10 (9.5) 75 (25.3) 565 (59.9)
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suggest that prescriptions for paroxetine were not replaced 
with fluoxetine, as the guidelines suggest, but with citalo-
pram, which became the most popular antidepressant by 
2004–2009. Although citalopram is effective for depression 
in adults [22], it has not been shown to be effective in chil-
dren and adolescents, in contrast to fluoxetine [5], which 
is the only second-generation antidepressant registered for 
the treatment of depression in young people in the Nether-
lands and many other countries. Antidepressants may also 
be prescribed for anxiety, particularly in younger children, 
but no randomized placebo-controlled trial of citalopram 
for that purpose appears to have been conducted in children 
and adolescents, although fluoxetine has been found effec-
tive [23, 24]. Among the SSRIs, citalopram has also been 
most strongly associated with QT interval prolongation 
(particularly at higher doses), which may increase the risk 
for torsade de pointes and sudden cardiac death [25, 26] 
and which may be an additional safety-related reason, apart 
from treatment-emergent suicidality, to prefer fluoxetine as 
a first-line treatment.
The starting dose of antidepressants was generally 
higher than recommended. In particular, teens were usually 
prescribed an adult starting dose and were only rarely pre-
scribed according to guidelines. Young children were pre-
scribed according to the guidelines much more frequently 
(58 %), but 10 % of children were actually prescribed the 
adult starting dose, which is two to four times higher than 
the recommended dose. Few differences between prescrib-
ers were apparent, although specialists prescribed some 
SSRIs in slightly lower starting doses than GPs. This may 
be due to the slightly lower mean age of children receiving 
SSRIs from specialists compared to GPs.
Sertraline and citalopram were more likely to be pre-
scribed according to the guidelines than other antidepres-
sants. For sertraline, this is likely because the recommended 
starting dose is higher than that of other antidepressants, 
especially for older children. If we had used the stricter 
guideline rather than the more lenient guideline, adherence 
would have been markedly lower (23 % overall). For cit-
alopram, the higher adherence to guidelines may be due to 
the availability of a liquid solution for citalopram, which 
facilitates low starting doses. In contrast, for fluoxetine, the 
tablet with the lowest dose currently available in the Neth-
erlands contains 20 mg (1 DDD), which makes it difficult 
to provide the recommended dose of 5 mg. Although liquid 
fluoxetine was previously available, it is not currently on 
the Dutch market. The difficulty of providing low doses of 
fluoxetine may be one reason for physicians’ preference for 
citalopram.
Several positive findings were also apparent. While GPs 
prescribed the majority of antidepressants in 1994–2003, 
prescriptions shifted to specialists over time, as recom-
mended by guidelines. We also found that the starting doses 
of some antidepressants, particularly citalopram, decreased 
over the study period, suggesting increasing awareness 
among physicians of the importance of low starting doses 
in young people. This finding agrees with a previous study 
in the USA showing increased prescription of low doses 
after the FDA warning in 2004 [18]. Finally, maintenance 
doses were nearly always in agreement with the guidelines; 
where they were not, this was usually because the dose was 
lower than recommended. In general, maintenance doses 
were very similar to starting doses. Up-titration from a low 
starting dose is recommended in the guidelines, but titra-
tion occurred in a minority of cases, probably because the 
starting dose was already within the maintenance range. 
Up-titration was more likely for second-generation antide-
pressants like citalopram and venlafaxine, for which a rela-
tively low starting dose was also more likely.
The number of young people initiating antidepres-
sant treatment decreased in the early 2000s, followed by a 
return to the level of 2001. Such a trend was also found in 
countries like the UK [13], but only to a slight extent or 
not at all in other countries, such as Canada [27] or Den-
mark [28]. The decrease in antidepressant initiation in 
young people was likely related to media coverage of the 
potential for treatment-emergent suicidality with antide-
pressant treatment [15], but this effect appears to have been 
transient.
Improving guideline adherence
Adherence to guidelines is often poor [29], and physicians’ 
prescription choices are influenced by a multitude of other 
factors besides guidelines and continuing medical educa-
tion. These influences may include the mass media (which 
may have been especially important with regard to the 
reduction in prescriptions for paroxetine) [15] and promo-
tion by pharmaceutical companies [30]. A large body of 
research has examined barriers and facilitators to the imple-
mentation of guidelines in clinical practice [31–33]. Adher-
ence is more likely when recommendations are specific and 
concrete rather than vague, when few additional resources 
are required for implementation, and when the evidence is 
strong and straightforward [33, 34]. While the recommen-
dation to initiate antidepressant treatment in children with 
fluoxetine is highly specific and does not require any addi-
tional resources, the evidence base for the use of fluoxetine 
in young people is relatively limited, although stronger 
than that for other antidepressants [5], which may affect 
physicians’ confidence in the recommendation. Dedicated 
effort, for example implementation interventions [35], may 
be needed to improve adherence to guidelines. A variety of 
interventions have been found to increase guideline adher-
ence, including provision of educational materials, audit 
and feedback, and reminders, but effects are modest [36]. 
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Educational meetings, which are a common form of contin-
uing medical education, also have small effects on improv-
ing guideline adherence [37]. A better understanding of the 
reasons behind physicians’ preference for citalopram may 
help clarify how guideline adherence could be improved.
Strengths and limitations
This study has several strengths. First, use of a general 
population prescription database excludes the possibility of 
recall bias and selection bias. Another important strength is 
that we specifically examined first prescriptions, in contrast 
to many previous studies. Furthermore, we included a long 
time period of 21 years, which allowed us to examine time 
trends and the possible influence of major events, such as 
the recognition of a link between antidepressants and suici-
dality in young people in 2003–2004. This long time period 
also included very recent data (up to and including 2014).
Some limitations must also be acknowledged. An impor-
tant limitation is that we did not have information about the 
indication for a prescription. As the guideline recommend-
ing fluoxetine is a guideline for the treatment of depres-
sion in young people, it may not apply to all prescriptions 
included herein. In particular, amitriptyline was frequently 
prescribed in children and adolescents (approximately 
15 % of all prescriptions), even though tricyclic antidepres-
sants are not recommended for the treatment of depression. 
Although we attempted to remove prescriptions for bed-
wetting and pain, the remaining patients may still have been 
treated with amitriptyline for complaints other than depres-
sion. A study among Dutch GPs suggested that SSRIs were 
usually prescribed for depression or anxiety, but tricyclics 
were often prescribed for bed-wetting, hyperactivity, ten-
sion headache or non-specific disease, and only rarely for 
depression [38]. Consequently, without information on 
the indication for amitriptyline prescriptions, it is difficult 
to determine whether these prescriptions were appropriate 
(although bed-wetting is the only approved indication for 
children and adolescents in the Netherlands). However, as 
the majority of SSRI prescriptions to children and adoles-
cents are for the purpose of treating depression [38], this 
limitation does not invalidate our finding that citalopram is 
preferred over fluoxetine, in contrast to the guideline. Fur-
thermore, low starting doses are important regardless of the 
indication and might even be of greater importance if anti-
depressants are prescribed for the treatment of anxiety, the 
most probable alternative indication for SSRIs, given the 
potential for increased anxiety early in treatment [39].
A second limitation of our study is that inpatient 
prescriptions are not included in the database. Conse-
quently, some ‘first prescriptions’ may actually have 
been repeat prescriptions after treatment initiation during 
hospitalization. However, only 3–4 % of all children who 
are treated in specialist mental health care are hospitalized 
in a year [40].
Conclusions
The guidelines on the treatment of depression in youth rec-
ommend fluoxetine as the treatment of choice. However, 
Dutch physicians appear to prefer citalopram over fluox-
etine, even though citalopram has not been studied exten-
sively and meta-analysis does not support its superiority 
over placebo in a pediatric population [5]. This is in con-
trast to findings from other countries, such as the United 
Kingdom, where antidepressant treatment in young people 
was most commonly initiated with fluoxetine (although 
citalopram has gained in popularity) [13]. Given that UK 
guidelines are similar to Dutch guidelines, this suggests 
that factors other than guidelines are likely to be the strong-
est driving forces behind (changes in) prescription patterns.
Furthermore, physicians tend to prescribe adult starting 
doses to older children. Although teens may weigh as much 
as adults, the possibility of a dose–response relationship 
with suicidality [8, 9] suggests that caution should be exer-
cised, even for older children. The same may also apply 
to young adults, for whom antidepressants have also been 
shown to increase the risk of suicidality [41]. Although 
starting doses were adjusted for children and preteens, 
they were still frequently higher than recommended. Main-
tenance doses, on the other hand, were usually within the 
recommended range.
Taken together, these findings show that adherence to 
guidelines for antidepressant initiation in children and 
adolescents is poor. In light of the limited evidence for 
the efficacy of some antidepressants and the potential for 
treatment-emergent suicidality, physicians should be made 
aware of the importance of guideline adherence and cau-
tious dosing of antidepressants in children and adolescents.
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